Q-omics provides the consensus-scored CHN1 profile across patient tissues and cancer cell-line models. CHN1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHN1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CHN1 RNA expression shows 19,488 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where CHN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHN1 survival associations across molecular data types. CHN1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHN1 RNA expression–survival associations across cancer types. High CHN1 expression shows unfavorable associations in ACC, MESO, UVM and STAD, but favorable associations in HNSC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHN1 RNA expression.
This table summarizes CHN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CHN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHN1 shows lower tumor expression in KICH and LUSC and higher tumor expression in HNSC, LIHC, COAD and KIRC. The HNSC box plot shows higher CHN1 RNA expression in tumor versus normal tissue (log2 FC = +1.952, t-test p < 0.001).
This table shows molecular features associated with CHN1 in patient tissues and cancer cell lines. In patient samples, CHN1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
